The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: The peptide with big claims and scant evidence STAT The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link